Metabolic Syndrome, Insulin Resistance and Systemic Inflammation as Risk Factors for Reduced Lung Function in Korean Nonsmoking Males by Lim, Seong Yong et al.
© 2010 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Metabolic Syndrome, Insulin Resistance and Systemic 
Inflammation as Risk Factors for Reduced Lung Function  
in Korean Nonsmoking Males
The aim of this study was done to assess the association of lung function with insulin 
resistance (IR), systemic inflammation, and metabolic syndrome (MetS). In 9,581 apparently 
healthy non-smoking male adults, pulmonary function, fasting glucose, insulin, lipid 
profiles and serum high-sensitivity C-reactive protein (hs-CRP) levels were measured, and 
homeostatic model assessment (HOMA) was used to assess IR. The presence of MetS was 
defined according to the AHA/NHLBI criteria. The prevalence of MetS was 19.3%. The odds 
ratio of MetS for restrictive ventilatory pattern was 1.55 (95% confidence interval, 1.12-
2.14), and that for obstructive ventilatory pattern was 1.39 (0.66-2.94) after adjustment for 
confounders. When subjects were divided in 4 groups according to quartiles of FVC or FEV1 
(% predicted [pred]), HOMA-IR significantly increased as the FVC or FEV1 (% predicted 
[pred]) decreased. Individuals in the lowest FVC or FEV1 quartile had the highest hs-CRP 
level. Prevalence of MetS increased as FVC or FEV1 (% predicted [pred]) quartiles decreased. 
The abdominal obesity, hs-CRP and HOMA-IR were the independent predictors for the 
lowest FVC and FEV1 (% predicted [pred]) even after adjustment for confounders. These 
results indicate that MetS, IR, and systemic inflammation are important risk factors for 
reduced lung function in nonsmoking Korean males. 
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ORIGINAL ARTICLE
Respiratory Diseases
INTRODUCTION
Impaired lung function, as measured by forced vital capacity 
(FVC) or forced expiratory volume in one second (FEV1), is known 
to be associated with increased prevalence and mortality of car-
diovascular diseases (1-3). Among the various cardiovascular 
risk factors, previous studies suggest the association of impaired 
lung function with insulin resistance (IR) and type 2 diabetes 
mellitus (4, 5). Furthermore, decreased FVC or FEV1 has been 
shown to be associated with persistent low grade systemic in-
flammation assessed by increased serum inflammatory mark-
ers, such as C-reactive protein (CRP) (5).
  Metabolic syndrome (MetS) refers to a cluster of abdominal 
obesity, dyslipidemia, hypertension, insulin resistance (IR), and 
prothrombotic states that predisposes to cardiovascular disease 
(6). Recently, many epidemiologic studies have highlighted the 
role of systemic inflammation in atherosclerosis and cardiovas-
cular disease (6, 7). Moreover, considerable attention is being 
paid to the relationship between systemic inflammation, IR and 
MetS (8, 9). 
  Although recent studies suggest the association of impaired 
lung function with MetS (10-13), such studies have several limi-
tations such as, small number of elderly study population (11), 
inclusion of smokers (10-12), and insufficient consideration for 
IR or systemic inflammatory markers (10-13). There have been 
few studies investigating the relationship between lung func-
tion and systemic inflammation, IR, and MetS simultaneously 
in a large number of nonsmoking healthy subjects. We there-
fore incorporated all components of MetS, IR, high-sensitivity 
(hs) CRP as a systemic inflammatory marker, and lung function 
variables into the analysis, and assessed the relationships in 9,581 
adult nonsmoking Korean males. We also evaluated whether 
the risk increases in a severity-dependent manner even within 
normal range of lung function. 
MATERIALS AND METHODS
Subjects
Between January to September 2005, a total of 33,546 male sub-
jects, who were inhabitants of either Seoul or Gyeonggi-do, Ko-Lim SY, et al.  •  Lung Function and Metabolic Syndrome
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rea underwent a health examination at the Health Promotion 
Centre in Kangbuk Samsung Hospital (a 640-bed tertiary uni-
versity hospital in Seoul, Korea). Among them, we recruited non-
smoking male subjects, in whom data for pulmonary function 
test, hs-CRP level and MetS parameters were available. Those 
subjects with a history of malignancy, asthma, chronic lung dis-
ease, pulmonary tuberculosis, liver disease, and severe cardio-
vascular disease were excluded. Final analysis was performed 
on 9,581 subjects. Self-reported alcohol intake, and physical ac-
tivity habits were obtained from questionnaire response. Ethics 
approval for patient recruitment and analysis of the data were 
obtained from the institutional review board of Kangbuk Sam-
sung Hospital (KBC 09093).
Measurement of lung function
Spirometry was performed as recommended by the American 
Thoracic Society (14), using Vmax 22 (SensorMedics, Yorba Lin-
da, CA). Absolute values of FVC and FEV1 were obtained and 
the percentage of predicted values (% pred) for FEV1 and FVC 
were calculated from following equations obtained in a repre-
sentative Korean population (15).
  Predicted FVC=-4.8434-(0.00008633×age
2 [years])+(0.05292 
                                         ×height [cm])+(0.01095×weight [kg])
  Predicted FEV1=-3.4132-(0.0002484×age
2 [years])+(0.04578×
                                         height [cm])
  The highest FVC and FEV1 value of the three or more tests with 
acceptable curves was used. Ventilatory patterns were defined as 
normal (FVC ≥80% and FEV1/FVC ≥0.7), restrictive (FVC <80% 
and FEV1/FVC ≥0.7; n=1,197; 12.5%), or obstructive pattern (FEV1/ 
FVC <0.7; n=134; 1.4%). In addition to ventilatory patterns, we 
also classified the patients according to the quartiles of FVC or 
FEV1 (% pred). Based on the FVC (% pred), the resulting four 
categories were as follows: quartile 1, <85%; quartile 2, ≥85%, 
<93%; quartile 3, ≥93%, <101%; quartile 4, ≥101%. In the same 
way, based on the FEV1 (% pred), the subjects were also divided 
into quartiles: quartile 1, <85%; quartile 2, ≥85%, <92%; quartile 
3, ≥92%, <100%; quartile 4, ≥100%. 
 
Anthropometric measurements and blood test
Systolic (SBP) and diastolic blood pressure (DBP) were mea-
sured according to the hypertension Detection and Follow-up 
Program protocol by using a mercury blood pressure device af-
ter the subjects had rested longer than 5 min (16). For the cases 
with a SBP higher than 140 mmHg and a DBP higher than 90 
mmHg, the BP was measured two more times after resting, and 
the average value was used. Body mass index (BMI) was calcu-
lated by weight (kg) divided by the squared height (m) (kg/m
2). 
The waist circumference (WC) was measured in the standing 
position, at the level of umbilicus, located midway between the 
lower costal margin (bottom of lower rib) and the iliac crest (top 
of pelvic bone). After 12 hr of fasting, blood glucose (FBG), total 
cholesterol (TC), triglyceride (TG), high-density lipoprotein 
cholesterol (HDL-C) and low-density lipoprotein-cholesterol 
(LDL-C) levels were obtained. The hexokinase method (Advia 
1650 Autoanalyzer; Bayer Diagnostics, Leverkusen, Germany) 
was used to measure blood glucose levels and an enzymatic 
colorimetric test was used to measure TC and TG levels. The 
selective inhibition method was used to measure HDL-C and a 
homogeneous enzymatic colorimetric test was used to measure 
LDL-C. The fasting serum insulin level was measured by immu-
noradiometric assay (RIABEAD II, Abbott, Tokyo, Japan), hav-
ing an intra-assay coefficient of variance of 1.2% to 1.9% and an 
inter-assay coefficient of variance of 1.4% to 3.3%. Serum hs-
CRP levels were measured using a nephelometric assay (BNII 
nephelometer, Dade Behring, Deerfield, IL, USA). The results 
were presented as milligrams per liter, and the limit of measure-
ment was 0.175 mg/L with a sample dilution of 1:20. 
  Insulin resistance status was calculated by using the homeo-
static model assessment-insulin resistance (HOMA-IR) (17). The 
calculation formula was as follows:
  HOMA-IR=(fasting insulin [μIU/mL]×fasting blood glucose 
                               [mM/L])/22.5
Definition of presence of metabolic syndrome
Based on the American Heart Association/National Heart, Lung, 
and Blood Institute (AHA/NHLBI) criteria with the WC defined 
by the Western Pacific Region of WHO for obesity (WPRO) cri-
teria, the diagnosis of MetS was made when the subject satis-
fied more than 3 categories among the 5 categories described 
below (6, 18): 1) Abdominal obesity: WC ≥90 cm; 2) TG ≥150 
mg/dL; 3) HDL-C <40 mg/dL; 4) Hypertension ≥130/85 mmHg; 
5) FBG ≥100 mg/dL.
Statistical analysis
Statistical analysis was performed with PASW statistics v.17.0 
package for Windows (SPSS Inc., Chicago, IL, USA). Data are 
presented as mean±SD. Descriptive statistics were used to de-
scribe the study population at baseline. The assessment for the 
normality of the variables was done with Kormogorov–Smirnov 
test, and the hs-CRP values were log-transformed as they did 
not follow normal distribution. The comparisons of mean val-
ues of the variables among the subdivided groups were per-
formed by Kruskal-Wallis test or one-way ANOVA, and multiple 
comparison tests were performed with post hoc analysis. The 
chi-square test was used for cross-tabulation analysis. Stepwise 
multiple logistic regression analyses were performed to evalu-
ate the associations between hs-CRP, HOMA-IR, MetS and the 
presence of lowest FVC and FEV1 (% pred) quartile after adjust-
ment for confounding factors, such as age and BMI. A 95% con-
fidence interval (CI) was determined for each risk. For all statis-
tical tests used, P value <0.05 was considered significant. Lim SY, et al.  •  Lung Function and Metabolic Syndrome
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RESULTS
Ventilatory patterns and metabolic syndrome, HOMA-IR, 
and hs-CRP
Clinical characteristics of the study population based on the 
ventilatory patterns are presented in Table 1. The mean age of 
the 9,581 participants was 40.9±8.9 yr. The prevalence of MetS 
was 19.3% for the whole subjects. Individuals in the restrictive 
pattern were more likely to have higher prevalence of MetS, to 
have higher WC, SBP, DBP, HOMA-IR, to have higher concen-
tration of FBG, TG, TC, LDL-C, and to have lower levels of HDL-
C. The crude odds ratio (OR) of MetS for restrictive pattern was 
1.71 (95% CI, 1.49-1.96). After adjustment of age, BMI, and phys-
ical activity, MetS and hs-CRP remained significant risk factors 
for restrictive pattern (adjusted odds ratio [ORa] [95% CI], 1.55 
[1.12-2.14] for MetS and ORa, 1.32 [1.16-1.50] for hs-CRP). Those 
patients with obstructive pattern showed significantly higher 
hs-CRP concentration compared with other groups. Multiple 
logistic regression analysis revealed that only hs-CRP was inde-
pendently associated with obstructive pattern (1.28 [1.02-1.61]). 
However, the OR and ORa of MetS for obstructive pattern were 
1.11 (0.73-1.70) and 1.39 (0.66-2.94), respectively. 
Quartiles of FVC and FEV1 (% pred) and component of 
metabolic syndrome
The mean values of BMI, WC, BP, serum FBG, TC, TG, LDL-C 
and insulin levels increased as the quartiles of FVC and FEV1 (% 
pred) decreased from quartile 4 to quartile 1. Mean HDL-C val-
ue decreased from quartile 4 to quartile 1 (Table 2).
Quartiles of FVC and FEV1 (% pred) and HOMA-IR, hs-CRP 
Mean HOMA-IR significantly increased as the FVC or FEV1 (% 
pred) decreased from quartile 4 to quartile 1. On post hoc anal-
ysis, the differences were significant among all groups (P<0.01). 
Those patients with lowest FEV1 (% pred) (Quartile 1) had a sig-
nificantly higher hs-CRP concentration compared with other 
three groups (Quartile 2, 3, 4) (Table 3).
Prevalence and odds ratio for the risk of MetS according to 
quartiles of FVC and FEV1 (% pred)
The lower quartile of FEV1  and FVC were independently asso-
ciated with MetS. After adjustment for age and BMI, MetS sig-
nificantly associated with reduced lung function (ORa [95% CI], 
1.21 [1.02-1.44] for FVC (% pred) quartile 1 and ORa, 1.38 [1.17-
1.63] for FEV1 (% pred) quartile1 when the highest quartile was 
considered as the reference category (Table 4). 
 
Table 1. Baseline subject characteristics according to the ventilatory patterns
Variables   All (n=9,581)   Normal (n=8,250) Restrictive pattern (n=1,197) Obstructive pattern (n=134)  P value
Age (yr)  40.9±8.9  40.2±8.1   44.5±11.5   47.6±10.6 <0.001
FVC (% predicted)    93.4±12.1    96.2±10.0 74.2±5.7   97.2±10.2 <0.001
FEV1 (% predicted)    93.2±12.1    95.5±10.7 78.9±8.8   81.6±10.3 <0.001
FEV1/FVC (%)  82.3±7.2  82.1±6.5 85.7±8.8 67.0±2.4 <0.001
Alcohol drinking (%)
   None
   ≤3 times/month
   1-2 times/week
   3-4 times/week
   ≥5 times/week
27.0
34.8
31.2
  6.0 
  1.0
26.4
35.3
31.5
  6.0
  0.8
29.7
32.1
30.1
  6.0
  2.0
37.2
26.7
27.9
  3.5
  4.7
  <0.001*
Regular Exercise (%)
   None 
   1-3 times/month
   at least once a week
  22.6
  37.1
  40.3
22.3
37.0
40.7
24.8
38.3
36.9
21.2
30.6
48.2
    0.062*
Prevalence of MetS (%)  19.3 18.2 27.7 19.8   <0.001*
BMI (kg/m
2)  24.1±2.7  24.0±2.6 24.8±2.9 23.8±2.4 <0.001
WC (cm)  82.3±7.5  81.9±7.3 87.0±7.9 80.2±7.5 <0.001
SBP (mmHg)  117±14  116±14 120±16 118±17 <0.001
DBP (mmHg)  79±9  79±9   80±10 79±9   0.023
FBG (mg/dL)  96.0±8.4  95.9±8.2 97.1±9.1 97.6±8.8   0.001
TG (mg/dL)  131.0±75.1  129.6±74.1 140.4±81.0 134.7±82.8 <0.001
HDL-C (mg/dL)    49.9±10.2    50.0±10.2 48.9±9.7   51.1±10.3   0.001
T-C (mg/dL)  191.8±31.7  191.5±31.5 194.3±32.6 193.8±30.8   0.044
LDL-C (mg/dL)  112.7±26.2  112.4±26.1 115.2±27.2 113.9±25.7 <0.001
Hs-CRP (mg/L)    1.2±0.3    1.2±0.2   1.4±0.3   3.1±0.3 <0.001
HOMA-IR    2.07±0.89    2.05±0.88   2.23±0.98   1.89±0.72 <0.001
Data are presented as mean±SD. Data were calculated using Kruskal-Wallis test or chi-square test*. 
BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment-insulin 
resistance; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; SBP, systolic blood pressure; T-C, total cholesterol; 
TG, triglyceride; WC, waist circumference. Lim SY, et al.  •  Lung Function and Metabolic Syndrome
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Multiple logistic regression analyses with lowest quartile 
of FVC and FEV1 (% pred) as the dependent variables
Stepwise multiple logistic regression analyses were performed 
to determine the relationship between the presence of the low-
est FVC and FEV1 (% pred) quartile and hs-CRP, HOMA-IR, and 
MetS after adjustment of age and BMI (Table 5). These analyses 
showed that higher hs-CRP, HOMA-IR, and abdominal obesity 
were independent predictors of the lowest FVC and FEV1 (% 
pred) quartiles. Similar results were obtained when the multi-
ple linear regression analyses were repeated using FVC and FEV1 
(% pred) as a continuous variables without dividing into quar-
tiles (Table 6). 
Table 2. Comparisons of metabolic profile by quartile of FVC and FEV1 (% pred)
Variables
FVC (% pred) quartiles
P for trend
I: <85% II: ≥85, <93% III: ≥93, <101% IV: ≥101%
BMI (kg/m
2) 24.6±2.9 24.3±2.7 24.0±2.6 23.5±2.5 <0.001
WC (cm) 85.8±7.5 83.9±7.1 82.0±7.0 79.5±6.9 <0.001
SBP (mmHg) 118.5±14.7 116.6±14.4 116.5±13.7 115.5±13.3 <0.001
DBP (mmHg) 78.9±9.5 78.6±9.5 79.1±9.2 78.2±8.8    0.004
FBG (mg/dL) 96.9±8.9 96.1±8.1 95.9±8.3 95.3±8.0 <0.001
TG (mg/dL) 139.2±79.9 135.5±78.5 128.0±71.3 121.3±68.7 <0.001
T-C (mg/dL) 193.3±32.1 193.1±31.4  191.6±31.4 189.3±31.5 <0.001
HDL-C (mg/dL) 48.9±9.8 49.7±9.9   50.1±10.2   51.0±10.6 <0.001
LDL-C (mg/dL) 114.4±26.5 113.7±25.9 112.4±26.1 110.3±26.1 <0.001
Insulin (μIU/mL)    9.09±3.69   8.92±3.49   8.64±3.44   8.09±3.13 <0.001
Variables
FEV1 (% pred) quartiles 
P for trend
I: <85% II: ≥85, <92% III: ≥92, <100% IV: ≥100%
BMI (kg/m
2) 24.3±2.8 24.1±2.8 24.0±2.6 23.9±2.5 <0.001
WC (cm) 84.0±7.6 82.4±7.4 81.7±7.4 80.8±7.1 <0.001
SBP (mmHg) 117.4±14.4 116.3±14.0 116.8±13.9 116.7±14.0    0.051
DBP (mmHg) 79.1±9.4 78.6±9.3 78.7±9.3 78.3±9.2    0.029
FBG (mg/dL) 96.5±8.6 96.0±8.2 95.9±8.3 95.5±8.3    0.001
TG (mg/dL) 138.7±79.3 133.5±76.6 130.0±77.1 121.7±65.5 <0.001
T-C (mg/dL) 194.5±32.2 192.2±32.1 191.1±31.8 189.6±31.4 <0.001
HDL-C (mg/dL)   49.3±10.0 49.7±9.8   49.9±10.2   50.8±10.7 <0.001
LDL-C (mg/dL) 114.8±26.7 112.9±25.6 112.2±26.2 110.9±26.2 <0.001
Insulin (μIU/mL)   9.05±3.72   8.85±3.52   8.62±3.44   8.22±3.10 <0.001
Data are presented as mean±SD. 
BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, 
systolic blood pressure; T-C, total cholesterol; TG, triglyceride; WC, waist circumference.
Table 3. Comparisons of mean values HOMA-IR and hs-CRP according to quartiles of FVC and FEV1 (% pred)
Variables
FVC (% pred) quartiles
I: <85% (n=2,395 ) II: ≥85, <93% (n=2,394 ) III: ≥93, <101% (n=2,395 ) IV: ≥101% (n=2,397)
HOMA-IR 2.19±0.96
a 2.12±0.89
b 2.05±0.87
c 1.91±0.80
d
hs-CRP (mg/L) 1.4±4.1
a 1.3±3.9
a  1.2 ±2.9
b 1.0±2.4
c
Variables
FEV1 (% pred) quartiles
I: <85% (n=2,394 ) II: ≥85, <92%(n=2,399 ) III: ≥92, <100% (n=2,395) IV: ≥100% (n=2,393 )
HOMA-IR 2.17±0.96
a  2.11±0.90
b  2.06±0.88
c 1.95±0.80
d
hs-CRP (mg/L) 1.6±5.4
a 1.1±2.3
b 1.2±2.9
b 1.0±2.4
b
Data are presented as mean±SD. 
HOMA-IR, homeostatic model assessment-insulin resistance; hs-CRP, high-sensitivity C-reactive protein. Superscript symbols show results of post hoc analysis: different letter 
superscripts denote a difference with P<0.01, e.g., mean values of HOMA-IR or hs-CRP values between quartiles of FVC and FEV1 (% pred) which were not significantly different 
share the same letter.
Table 4. Prevalence and adjusted odds ratio for the risk of metabolic syndrome accor-
ding to quartiles of FVC and FEV1 (% pred)
FVC (% pred) quartiles Prevalence (%)* Odds ratio 95% CI P value
I (<85%) 6.3 1.21 1.02–1.44     0.032
II (≥85, <93%) 5.1 1.10 0.92–1.31 >0.05
III (≥93, <101%) 4.6 1.14 0.96–1.36 >0.05
IV (≥101%) 3.3 1 – –
FEV1 (% pred) quartiles Prevalence (%)* Odds ratio 95% CI P value
I (<85%) 6.0 1.38 1.17–1.63  <0.001
II (≥85, <92%) 4.8 1.17 0.98–1.39 >0.05
III (≥92, <100%) 4.6 1.21 1.02–1.43     0.033
IV (≥100%) 3.9 1 – –
*Chi-square test for linear trend; P<0.001. 
CI, confidence interval.Lim SY, et al.  •  Lung Function and Metabolic Syndrome
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DISCUSSION
The major finding of this study is that when the study popula-
tion was divided into quartiles based on FVC or FEV1 (% pred), 
there were significant increase in the prevalence of MetS, risk of 
being insulin resistant, and concentration of serum hs-CRP as 
the lung function decreased even within normal range of lung 
function. Multiple logistic regression analysis revealed that ab-
dominal obesity, HOMA-IR, and serum hs-CRP are indepen-
dent risk factors for the lowest lung function. Moreover, accord-
ing to the results based on ventilatory patterns, MetS was more 
significantly related with restrictive pattern, and hs-CRP was a 
significant risk factor for both restrictive and obstructive pat-
tern. These results clearly indicate that lung function and serum 
hs-CRP, IR and MetS are closely related. 
  One of the strong points we observed in this study was that 
systemic inflammation as determined by hs-CRP was strongly 
related to both the restrictive and obstructive ventilatory pat-
tern as well as inversely linked with lowest FVC or FEV1 (% pred) 
quartile, suggesting a crucial role in the decline of lung function. 
These results extend previous finding demonstrating an associ-
ation of increased CRP level with lung function decline (19), or 
obstructive and restrictive lung diseases (20). Aronson et al. (21), 
also showed inverse association between lung function and CRP 
level in apparently healthy subjects and in the subgroup of nev-
er-smokers. Considering the facts that adipokines secreted by 
visceral adipose tissue can negatively affect lung function (22) 
and that WC is known to be the main determinant of elevated 
CRP in MetS (23), a plausible mechanism for the inverse asso-
ciation between systemic inflammation and reduced lung func-
tion in this study could be best explained by the role of MetS or 
abdominal obesity. Adipokines promote systemic inflamma-
tion, which subsequently may lead to activate airway inflam-
mation and decline in lung function. However, it is still unclear 
whether initially higher level of systemic inflammation may ac-
celerate lung function decline. In 16 years of follow-up study in 
elderly by Jiang et al. (24), baseline CRP levels failed to show sig-
nificant correlation with future lung function, whereas baseline 
fibrinogen levels showed inverse correlation with future lung 
function. To fully elucidate this association, a large prospective 
study would be needed. 
  This study showed that the risk of being relatively insulin re-
sistant, as measured by HOMA-IR, was significantly increased 
as the lung function decreased. We also found that together with 
hs-CRP, HOMA-IR was the independent risk factor for reduced 
FVC, FEV1 (% pred). Our study clearly demonstrated a direct 
impact of the MetS or IR per se on the development of reduced 
lung function in a severity-dependent manner even after adjust-
ment for confounding factors. There have been a few studies that 
analyzed the relationship between lung function and HOMA-
IR. In the longitudinal 7-yr follow-up study performed in ini-
tially nondiabetic 1,436 males and 896 females by Engström et 
al. (25), subjects with a reduced FVC had an increased risk of 
developing IR, defined by highest quartile of HOMA-IR. In an-
other study by Lawlor et al. (5), HOMA score decreased as FEV1 
and FVC increased in 3,911 women enrolled in British Women’s 
Heart and Health Study. As both reduced lung function and the 
Table 5. Multiple logistic regression analyses with lowest quartile of FVC and FEV1 (% pred) as dependent variables
Variables
FVC (% pred) lowest quartile FEV1 (% pred) lowest quartile
Odds ratio 95% CI P value Odds ratio 95% CI P value
Abdominal Obesity 1.82 1.41–2.36 <0.001 1.27 1.01–1.61    0.039
HOMA-IR quartile
   I
   II
   III
   IV
1
1.05
1.31
1.51
0.79–1.41
0.99–1.74
1.13–2.00
   0.734
   0.056
   0.005
1
1.19
1.33
1.47
0.94–1.50
1.06–1.68
1.16–1.86
  0.149
  0.015
  0.002
hs-CRP quartile
   I
   II
   III
   IV
1
1.25
1.38
1.62
0.92–1.69
1.04–1.83
1.22–2.15
   0.153
   0.027
   0.001
1
1.47
1.48
1.85
1.15–1.87
1.17–1.87
1.46–2.34
  0.002
  0.001
<0.001
Adjusted for age and body mass index. Abdominal obesity defined by waist circumference ≥90 cm. 
CI, confidence interval; HOMA-IR, homeostatic model assessment insulin resistance; hs-CRP, high-sensitivity C-reactive protein.  
Table 6. Regression coefficients of indices of metabolic syndrome, HOMA-IR, and hs-
CRP predicting FVC and FEV1 (% pred) as dependent variables
Variables
FVC (% pred) FEV1 (% pred) 
β (SE) P value β (SE) P value
WC -0.507 (0.04) <0.001 -0.339 (0.05) <0.001
SBP -0.012 (0.02) 0.535 0.011 (0.02) 0.608
DBP 0.001 (0.03) 0.970 -0.021 (0.03) 0.516
HDL-C 0.011 (0.02) 0.545 0.028 (0.02) 0.173
TG -0.001 (0.003) 0.564 -0.006 (0.003) 0.024
HOMA-IR -0.890 (0.22) <0.001 -0.595 (0.25) 0.016
hs-CRP -0.974 (0.19) <0.001 -1.240 (0.21) <0.001
Data were calculated using multiple linear regression analysis and adjusted for age 
and body mass index. 
DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, 
homeostatic model assessment insulin resistance; hs-CRP, high-sensitivity C-reactive 
protein; SBP, systolic blood pressure; TG, triglyceride; WC, waist circumference.Lim SY, et al.  •  Lung Function and Metabolic Syndrome
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presence of IR have been associated with increased cardiovas-
cular mortality, the coexistence or the association of IR with re-
duced lung function might have considerable impact on future 
health. 
  Previous studies have reported that reduced lung function is 
associated with MetS (10-13). In a recent study performed in 
2,396 Japanese, Nakajima et al. (12), showed that CRP levels and 
FVC (% pred), but not FEV1/FVC, were significantly associated 
with MetS. They also demonstrated that restrictive lung func-
tion was associated with MetS in a severity-dependent manner. 
Nonetheless, their study had an important limitation like the 
study by Lin et al. (10), in that IR status was not considered in 
the evaluation, which is the most fundamental element for the 
association between reduced lung function and MetS. Leone et 
al. (13) also reported a positive independent relationship be-
tween lung function impairment (both obstructive and restric-
tive pattern) and MetS in a recent large population-based study, 
in which abdominal obesity was found to be playing a core role. 
However, IR and systemic inflammation were not assessed ad-
equately in their analysis. Moreover, another important limita-
tion in the majority of previous studies was that they only fo-
cused on the relationship between the abnormal lung function 
and MetS. Engström et al. (25) identified that the risk for the fu-
ture development of IR has decreased by ten percent for each 
ten percent increase in FVC1 (% pred). In the National Health 
and Nutritional Examination Survey follow-up study, Sin et al. 
(26) also found that even a modest decline in FEV1 (% pred) from 
a mean of 109% to 88 % was associated with a five-fold increase 
in mortality from ischemic heart disease. Based on these results, 
we assumed that it is more reasonable to analyze the relation-
ship between lung function, systemic inflammation, IR and MetS, 
further expanding to the categories above the normal range of 
lung function whether there is a stepwise increment in the rela-
tive risk for the development of IR and MetS as the lung function 
decreases. In this study, the prevalence and the risk for MetS 
gradually increased as the both FVC and FEV1 (% pred) decreas-
ed from highest to lowest quartile. This observation is consis-
tent with our assumption that the prevalence of MetS increases 
even within the normal range of FVC and FEV1 (% pred). How-
ever, it is difficult to draw clear conclusion about cause-effect 
relationship or clinical impact based on this study alone. Fur-
ther studies are required to clarify the causal relationship and 
to assess clinical outcomes including long-term changes in lung 
function as well as the therapeutic effect of MetS on the rate of 
lung function decline.  
  There are several explanations for the relationship between 
reduced lung function and MetS. MetS is a cluster of disease 
comprised of multiple cardiovascular risk factors such as IR, 
dyslipidemia, glucose intolerance and hypertension, most of 
which could stem from one cause, visceral obesity (27). Obesity 
has long been shown to be related to cause physiologic impair-
ments in respiratory system (28): airflow limitation with reduc-
tion of both FEV1 and FVC; reduction in lung volumes, espe-
cially expiratory reserve volume (ERV) and functional residual 
capacity (FRC), which predispose toward a decrease in periph-
eral airway diameter; reduction in respiratory system compli-
ance, as well as an increase in oxygen cost of breathing and air-
way hyperresponsiveness (AHR). Taken together, decrease in 
retractive forces of the lung parenchyma on the airways at low 
lung volume in obese people, lead to reduce airway caliber and 
increased AHR, which potentially causing detrimental effect on 
lung function. The association of obstructive lung function with 
MetS could be explained by obesity, and subsequent systemic 
inflammation and by the role of adipokines (29). 
   This study has several limitations. First, because obstructive 
pattern was found only in 1.4% of these participants without 
post-bronchodilator assessment and the diagnosis of restrictive 
pattern was made without total lung capacity measurement, 
analysis according to the ventilatory patterns was not sufficient-
ly adequate. Moreover, since FEV1 is dependent on the FVC, 
quartiles of FEV1 values may not exclusively reflect the degree 
of true airflow limitation. Further clinical studies are warranted 
exploiting the measurement of total lung capacity and bron-
chodilator test to precisely define the ventilatory patterns. Sec-
ond, since this study used a cross-sectional design, longitudinal 
studies are needed to investigate the interactions between lung 
function, inflammation, IR, MetS and their relation with future 
cardiovascular disease. In addition, though we found statistical-
ly significant trend, the differences between values of metabolic 
parameters in lung function quartiles were small. The clinical 
significance of these small differences remains to be elucidated, 
and needed to be verified in future prospective longitudinal study, 
whether small different degree of metabolic perturbations would 
be associated with different incidence of cardiovascular events 
or different rate of lung function decline.
  In conclusion, this study clearly showed that metabolic syn-
drome, insulin resistance, and systemic inflammation are im-
portant risk factors for reduced lung function in nonsmoking 
Korean males. 
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